Whitehurst C - Search Results

1

Positive reciprocal regulation of ubiquitin C-terminal hydrolase L1 and beta-catenin/TCF signaling.

Bheda A, Yue W, Gullapalli A, Whitehurst C, Liu R, Pagano JS, Shackelford J. Bheda A, et al. Among authors: whitehurst c. PLoS One. 2009 Jun 18;4(6):e5955. doi: 10.1371/journal.pone.0005955. PLoS One. 2009. PMID: 19536331 Free PMC article.

2

The Epstein-Barr virus (EBV) deubiquitinating enzyme BPLF1 reduces EBV ribonucleotide reductase activity.

Whitehurst CB, Ning S, Bentz GL, Dufour F, Gershburg E, Shackelford J, Langelier Y, Pagano JS. Whitehurst CB, et al. J Virol. 2009 May;83(9):4345-53. doi: 10.1128/JVI.02195-08. Epub 2009 Feb 25. J Virol. 2009. PMID: 19244336 Free PMC article.

3

Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.

Wang FZ, Roy D, Gershburg E, Whitehurst CB, Dittmer DP, Pagano JS. Wang FZ, et al. J Virol. 2009 Dec;83(23):12108-17. doi: 10.1128/JVI.01575-09. Epub 2009 Sep 16. J Virol. 2009. PMID: 19759127 Free PMC article.

4

Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9.

Bentz GL, Whitehurst CB, Pagano JS. Bentz GL, et al. J Virol. 2011 Oct;85(19):10144-53. doi: 10.1128/JVI.05035-11. Epub 2011 Jul 27. J Virol. 2011. PMID: 21795333 Free PMC article.

5

Epstein-Barr virus BPLF1 deubiquitinates PCNA and attenuates polymerase η recruitment to DNA damage sites.

Whitehurst CB, Vaziri C, Shackelford J, Pagano JS. Whitehurst CB, et al. J Virol. 2012 Aug;86(15):8097-106. doi: 10.1128/JVI.00588-12. Epub 2012 May 23. J Virol. 2012. PMID: 22623772 Free PMC article.

6

Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.

Whitehurst CB, Sanders MK, Law M, Wang FZ, Xiong J, Dittmer DP, Pagano JS. Whitehurst CB, et al. J Virol. 2013 May;87(9):5311-5. doi: 10.1128/JVI.03505-12. Epub 2013 Feb 28. J Virol. 2013. PMID: 23449792 Free PMC article.

7

The Rad6/18 ubiquitin complex interacts with the Epstein-Barr virus deubiquitinating enzyme, BPLF1, and contributes to virus infectivity.

Kumar R, Whitehurst CB, Pagano JS. Kumar R, et al. J Virol. 2014 Jun;88(11):6411-22. doi: 10.1128/JVI.00536-14. Epub 2014 Mar 26. J Virol. 2014. PMID: 24672041 Free PMC article.

8

LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.

Bentz GL, Moss CR 2nd, Whitehurst CB, Moody CA, Pagano JS. Bentz GL, et al. J Virol. 2015 Aug;89(15):7465-77. doi: 10.1128/JVI.00711-15. Epub 2015 May 6. J Virol. 2015. PMID: 25948750 Free PMC article.

9

Knockout of Epstein-Barr virus BPLF1 retards B-cell transformation and lymphoma formation in humanized mice.

Whitehurst CB, Li G, Montgomery SA, Montgomery ND, Su L, Pagano JS. Whitehurst CB, et al. mBio. 2015 Oct 20;6(5):e01574-15. doi: 10.1128/mBio.01574-15. mBio. 2015. PMID: 26489865 Free PMC article.

10

The Translesion Polymerase Pol η Is Required for Efficient Epstein-Barr Virus Infectivity and Is Regulated by the Viral Deubiquitinating Enzyme BPLF1.

Dyson OF, Pagano JS, Whitehurst CB. Dyson OF, et al. J Virol. 2017 Sep 12;91(19):e00600-17. doi: 10.1128/JVI.00600-17. Print 2017 Oct 1. J Virol. 2017. PMID: 28724765 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters